Citizens upgraded Stryker (SYK) to Outperform from Market Perform with a $440 price target The shares lagged peers and its own historical returns performance in 2025, trading down 12% from its yearly high in late July, the analyst tells investors in a research note. Citizens believes Stryker “remains a best-in-breed player” in medical technology. It cites the stock’s “reasonable” valuation at current share levels for the upgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: